$1.86
1.59% yesterday
Nasdaq, Dec 24, 10:35 pm CET
ISIN
US3724461047
Symbol
GNPX

Genprex, Inc. Stock price

$1.86
-0.94 33.57% 1M
-10.64 85.12% 6M
-40.72 95.63% YTD
-44.55 95.99% 1Y
-1,998.14 99.91% 3Y
-9,378.14 99.98% 5Y
-9,398.14 99.98% 10Y
-9,398.14 99.98% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.03 1.59%
ISIN
US3724461047
Symbol
GNPX
Industry

Key metrics

Basic
Market capitalization
$4.3m
Enterprise Value
$3.2m
Net debt
positive
Cash
$1.1m
Shares outstanding
1.0m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.6
Financial Health
Equity Ratio
39.3%
Return on Equity
-1,320.1%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-24.7m
Net Income
- | $-1.3m
Free Cash Flow
$-15.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -16.8%
Net Income
- | 94.0%
Free Cash Flow
17.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-15.1
Short interest
16.3%
Employees
15
Rev per Employee
$0.0
Show more

Is Genprex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Genprex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Genprex, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Genprex, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Genprex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
21% 21%
-
- Research and Development Expense 11 11
40% 40%
-
-21 -21
32% 32%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -21 -21
32% 32%
-
Net Profit -21 -21
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Genprex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genprex, Inc. Stock News

Neutral
PRNewsWire
about one month ago
Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa® Gene Therapy with Tagrisso® AUSTIN, Texas , Nov. 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the publication of data from its Acclaim-1 Phase 1 clinical tri...
Neutral
PRNewsWire
about one month ago
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 Clinical Trials Supported by FDA Fast Track Designation AUSTIN, Texas , Nov. 19, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and di...
Neutral
PRNewsWire
about one month ago
Strengthens Intellectual Property Portfolio and Provides Protection for Therapeutic Combination in Acclaim-3 Clinical Trial AUSTIN, Texas , Nov. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Paten...
More Genprex, Inc. News

Company Profile

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Head office United States
CEO Ryan Confer
Employees 15
Founded 2009
Website www.genprex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today